#None #START Center #Oncology Trials #Trialing

START and Trialing: A Strategic Partnership to Improve Oncology Clinical Trials Access

In a groundbreaking collaboration that aims to expand access to oncology clinical trials, the START Center for Cancer Research has announced a new partnership with Trialing, a platform committed to connecting healthcare providers with essential clinical trial information. This alliance is set to significantly enhance how oncologists and patients access innovative cancer therapies, addressing one of the most pressing challenges in cancer research today: accessibility.

Streamlined Referral Process

The START Center, recognized as the world's largest community-based network for early-phase oncology trials, aims to leverage Trialing's existing platform to provide physicians with curated information about ongoing clinical trials. By utilizing Trialing's advanced technology and streamlined workflows, physicians can more efficiently identify, evaluate, and refer patients to the most appropriate studies available across Europe.

“Access remains one of the greatest barriers in oncology clinical research,” said Nick Slack, MBE, Chairman and CEO of START. He emphasized that this partnership would engage oncologists on a platform they trust, allowing for seamless communication about their active trials. The collaboration strives to not only enhance the referral process but also to significantly improve oncologist awareness regarding the various clinical trials being conducted.

Enhanced Communication

Through this partnership, START intends to distribute real-time updates about clinical trials to medical oncologists, ensuring they are notified whenever enrollment opportunities arise. The dynamic nature of Trialing’s platform, which features medical evaluation and data analysis capabilities supported by an in-house medical team, is designed to empower physicians, enabling them to provide timely referrals for patients seeking participation in clinical trials.

“We are excited about this partnership with START, as it embodies our commitment to enhancing access to clinical trials through smarter solutions,” stated Max Hardy-Werbin, CEO of Trialing. He added that the collaboration offers a unified platform for sharing essential trial information, thereby cutting down delays that often hinder patient access to groundbreaking therapies.

Focus on Early-Phase Trials

The START Center focuses heavily on early-phase clinical trials aimed at developing novel anti-cancer agents. With over 1,000 trials conducted and a steady increase in the number of clinical trial sites across Europe, START is committed to bridging the gap between clinical research and patient care. By collaborating with Trialing, START hopes to improve transparency in clinical trial access, leading to better communication and referral pathways among community oncologists and referring physicians.

Dr. Emiliano Calvo, President of START Europe, stated, “Clinical trial awareness and referral efficiency are critical to advancing cancer care. Partnering with Trialing enables us to effectively share study availability with oncologists and ensure that patients are referred at the precise moment when enrollment slots open up.”

Conclusion

Overall, this strategic partnership marks a significant milestone in the quest to enhance cancer care through clinical trial participation. By merging START’s vast network of research sites with Trialing’s innovative platform, the collaboration is designed to remove barriers to trial participation, fortifying the infrastructure needed to deliver innovative treatment options to cancer patients faster and more efficiently than ever.

For more information on how this partnership unfolds and the continued efforts to transform cancer research, visit START's official website and Trialing’s platform here.